Who is sponsoring NCT04331535?

NCT04331535 is sponsored by Boston VA Research Institute, Inc..

What drugs are being tested in NCT04331535?

Interventions in NCT04331535: Polygenic risk score (PRS).

What condition does NCT04331535 study?

NCT04331535 studies Coronary Artery Disease, Atrial Fibrillation, Type 2 Diabetes, Colorectal Cancer, Breast Cancer, Prostate Cancer.

Is NCT04331535 still recruiting?

NCT04331535 is currently status unknown. Last updated 3 October 2022.

Last reviewed 2022-10-03 · How we verify

NCT04331535: GenoVA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Genomic Medicine at VA Study

Status unknown NA Last updated 3 October 2022

What this trial tests

NA trial testing Polygenic risk score (PRS) in Coronary Artery Disease in 1,076 participants. Status unknown.

Timeline

17 July 2020

Primary endpoint
30 September 2025

30 September 2025

Quick facts

Lead sponsor	Boston VA Research Institute, Inc.
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	screening
Enrollment	1,076
Start date	17 July 2020
Primary completion	30 September 2025
Estimated completion	30 September 2025
Sites	1 location across United States

Drugs / interventions tested

Polygenic risk score (PRS)

Conditions studied

Coronary Artery Disease — all drugs for Coronary Artery Disease →
Atrial Fibrillation — all drugs for Atrial Fibrillation →
Type 2 Diabetes — all drugs for Type 2 Diabetes →
Colorectal Cancer — all drugs for Colorectal Cancer →

Sponsor

Boston VA Research Institute, Inc.

Who can join

Adults 50 to 70, any sex, with Coronary Artery Disease or Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial will determine the clinical effectiveness of polygenic risk score testing among patients at high genetic risk for at least one of six diseases (coronary artery disease, atrial fibrillation, type 2 diabetes mellitus, colorectal cancer, breast cancer, or prostate cancer), measured by time-to-diagnosis of prevalent or incident disease over 24 months.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Development of a clinical polygenic risk score assay and reporting workflow.
Hao L, Kraft P, Berriz GF, Hynes ED, et al · · 2022 · cited 159× · PMID 35437332 · DOI 10.1038/s41591-022-01767-6
Clinical utility of polygenic risk scores for coronary artery disease.
Klarin D, Natarajan P. · · 2022 · cited 118× · PMID 34811547 · DOI 10.1038/s41569-021-00638-w
The GenoVA study: Equitable implementation of a pragmatic randomized trial of polygenic-risk scoring in primary care.
Vassy JL, Brunette CA, Lebo MS, MacIsaac K, et al · · 2023 · cited 21× · PMID 37922883 · DOI 10.1016/j.ajhg.2023.10.001
Performance of EHR classifiers for patient eligibility in a clinical trial of precision screening.
Alexander NVJ, Brunette CA, Guardino ET, Yi T, et al · · 2022 · cited 3× · PMID 36115637 · DOI 10.1016/j.cct.2022.106926

Verify or expand the search:

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB · recruiting
NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting

Other Boston VA Research Institute, Inc. trials

Trials by the same sponsor.

NCT05800782 — Face Perception vs. Memory Training to Improve Face Recognition in Developmental Prosopagnosia · NA · unknown
NCT05299749 — Real-time fMRI Neurofeedback in Patients With Schizophrenia and Auditory Hallucinations · NA · recruiting
NCT05028998 — COVID-19-Related Opioid Treatment Policy Evaluation · unknown
NCT04799340 — Computer-based Training of Face Recollection to Improve Face Recognition in Developmental Prosopagnosia · NA · unknown
NCT04225130 — Decreasing Suicide Risk Among Service Members With Posttraumatic Stress · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04331535 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Boston VA Research Institute, Inc.
Last refreshed: 3 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04331535.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing